Bellerophon Therapeutics Stock Fundamentals
| BLPHDelisted Stock | USD 0.71 0.01 1.43% |
Bellerophon Therapeutics fundamentals help investors to digest information that contributes to Bellerophon Therapeutics' financial success or failures. It also enables traders to predict the movement of Bellerophon Pink Sheet. The fundamental analysis module provides a way to measure Bellerophon Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bellerophon Therapeutics pink sheet.
Bellerophon |
Bellerophon Therapeutics Company Operating Margin Analysis
Bellerophon Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Bellerophon Therapeutics Operating Margin | (2.48) % |
Most of Bellerophon Therapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bellerophon Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Bellerophon Therapeutics has an Operating Margin of -2.4798%. This is 92.93% lower than that of the Health Care Equipment & Supplies sector and 97.79% lower than that of the Health Care industry. The operating margin for all United States stocks is 54.99% lower than that of the firm.
Bellerophon Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bellerophon Therapeutics's current stock value. Our valuation model uses many indicators to compare Bellerophon Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bellerophon Therapeutics competition to find correlations between indicators driving Bellerophon Therapeutics's intrinsic value. More Info.Bellerophon Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bellerophon Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bellerophon Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Did you try this?
Run Money Managers Now
Money ManagersScreen money managers from public funds and ETFs managed around the world |
| All Next | Launch Module |
Bellerophon Fundamentals
| Return On Equity | -1.39 | |||
| Return On Asset | -0.6 | |||
| Profit Margin | (2.20) % | |||
| Operating Margin | (2.48) % | |||
| Current Valuation | (9.32 M) | |||
| Shares Outstanding | 12.23 M | |||
| Shares Owned By Insiders | 3.97 % | |||
| Shares Owned By Institutions | 45.08 % | |||
| Number Of Shares Shorted | 90.45 K | |||
| Price To Earning | 5.33 X | |||
| Price To Book | 1.05 X | |||
| EBITDA | (22.39 M) | |||
| Net Income | (19.83 M) | |||
| Cash And Equivalents | 16.33 M | |||
| Cash Per Share | 1.71 X | |||
| Total Debt | 203 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 3.12 X | |||
| Book Value Per Share | 0.46 X | |||
| Cash Flow From Operations | (17.77 M) | |||
| Short Ratio | 1.26 X | |||
| Earnings Per Share | (0.34) X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 18 | |||
| Beta | 0.55 | |||
| Market Capitalization | 1.25 M | |||
| Total Asset | 7.93 M | |||
| Retained Earnings | (252.08 M) | |||
| Working Capital | 2.16 M | |||
| Current Asset | 29.45 M | |||
| Current Liabilities | 8.07 M | |||
| Z Score | -49.75 | |||
| Net Asset | 7.93 M |
About Bellerophon Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bellerophon Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bellerophon Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bellerophon Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. Bellerophon Ther operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Bellerophon Pink Sheet
If you are still planning to invest in Bellerophon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellerophon Therapeutics' history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |